Milestone received $13 million in equity financing

Montreal's Milestone Pharmaceuticals Inc has completed a $13-million equity financing to further development of its flagship compound (MSP-2017) for the treatment of a cardiac arrhythmia called paroxysmal supraventricular tachycardia (PSVT). The financing was provided by Pappas Ventures, the BDC Health Venture Fund, GO Capital, Fonds de solidarite FTQ, and previous investors iNovia Healthcare and Fonds Bio-Innovation. The preclinical company hopes MSO-2917 will become an effective "pill-in-the-pocket" to terminate acute PSVT episodes without having to resort to the emergency room, thereby driving down health care costs....